A true partner in the pursuit of expanded healthspan
Cambrian’s scientists and company-building experts closely partner with research teams, offering scientific and organizational insights and support for a significant edge in a complex, rapidly evolving field.
The Cambrian model of bringing together expert scientists and experienced company-builders represents an innovative approach to solving complex challenges around the biology of aging.
“Over the next 10 or 15 years, Cambrian wants to bring the way that we treat the diseases of aging into the 21st century by preventing them from happening, instead of waiting for people to get sick, the same way that we learned how to prevent and reverse the pathologies of infectious diseases like smallpox and polio in the 20th century.”
CEO and Founder of Cambrian Biopharma
We combine scientific rigor with an audacious mission: developing transformative, effective and safe therapies to extend healthspan. A crucial aspect of our vision is making these therapies widely available, wherever possible.
PM360: Cambrian is Using a New Drug Discovery Model to Solve the Science of Aging
“Cambrian Biopharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co- founder James Peyer about this new model, while he decided to focus on the biology of aging, and more.”
Foresight Institute Biotech & Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors”
“The Foresight Institute is a non-profit organization that was founded in 1986 on a vision of coming revolutions in technology that will bring extraordinary opportunities, as well as unprecedented challenges. Cambrian Biopharma CEO James Peyer led this webinar for their Biotech & Health Extension series, focused on strategies for finding and building geroperotective drugs.”
Longevity.Technology: Cambrian Biopharma – CEO James Peyer Q&A
“Longevity biotech exclusive Q&A with Cambrian Biopharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.”
Longevity.Technology: Cambrian Biopharma – Juliette Han Q&A
“Longevity biotech exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer, Juliette Han”
Careers in Discovery with Tom Froggatt: Tauhid Ali, Cambrian Biopharma
“Tauhid Ali is the Executive Vice President of Translational & Clinical Science for Cambrian Biopharma, a new kind of Biotech company with a real opportunity to disrupt the traditional business models of the sector. Tauhid joins us on Careers in Discovery to talk about his life in Clinical Science, as well as: Geroscience, the wider impact it has and why it could be the next big thing in Biotech, working as part of a “DisCo”, and the need for "patient capital" in drug development”